AstraZeneca PLC (STO:AZN)
1,385.50
-21.50 (-1.53%)
Jul 25, 2025, 5:29 PM CET
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B USD in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$54.98B
Revenue Growth
+15.48%
P/S Ratio
3.89
Revenue / Employee
$583.05K
Employees
94,300
Market Cap
2,144.29B SEK
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Swedish Orphan Biovitrum AB | 26.97B |
Sectra AB | 3.31B |
Getinge AB | 35.50B |
Camurus AB | 2.27B |
Medicover AB | 25.22B |
Asker Healthcare Group AB | 15.88B |
AddLife AB | 10.44B |
Bonesupport Holding AB | 1.06B |
AstraZeneca News
- 1 day ago - AstraZeneca gets EU backing for eco-friendly inhaler version - Seeking Alpha
- 1 day ago - AstraZeneca's eco-friendly version of smoker's lung inhaler gets EU panel backing - Reuters
- 2 days ago - AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate - Benzinga
- 2 days ago - AstraZeneca succeeds in late-stage trial for myasthenia gravis therapy - Seeking Alpha
- 2 days ago - AstraZeneca's immune disorder drug succeeds in late-stage trial - Reuters
- 3 days ago - What's Driving the Market Sentiment Around AstraZeneca? - Benzinga
- 3 days ago - Five years after COVID, pharma shares languish in US policy limbo - Reuters
- 4 days ago - 5 Ideal "Safer" Dividend Buys From Bloomberg's July Watch List - Seeking Alpha